American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 205-208 , August 2008

Racial Differences in Mortality and ESRD

  • Keith Norris, MD

      Affiliations

    • Charles Drew University, Los Angeles, California
    • David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
    • Corresponding Author InformationAddress correspondence to Keith C. Norris, MD, Charles R. Drew University of Medicine and Science, 1731 East 120th St, Los Angeles, CA 90059.
    • ,
  • Rajnish Mehrotra, MD

      Affiliations

    • David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California
    • Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California
    • ,
  • Allen R. Nissenson, MD

      Affiliations

    • David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

References 

  1. Murray CJL, Kulkarni SC, Michaud C, et al. Eight Americas: Investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med. 2006;3:1513–1524
  2. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233–1241
  3. Agodoa L, Eggers P. Racial and ethnic disparities in end-stage kidney failure-survival paradoxes in African-Americans. Semin Dial. 2007;20:577–585
  4. US Renal Data System: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2007;
  5. Robinson BM, Joffe MM, Pisoni RL, Port FK, Feldman HI. Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol. 2006;17:2910–2918
  6. Norris K, Nissenson AR. Race, gender, and socioeconomic disparities in CKD in the United States. J Am Soc Nephrol. 2008;June 4, [Epub ahead of print]
  7. Powe NR. Reverse race and ethnic disparities in survival increase with severity of chronic kidney disease: what does this mean?. Clin J Am Soc Nephrol. 2006;1:905–906
  8. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808
  9. Daumit GL, Hermann JA, Coresh J, et al. Use of cardiovascular procedure among black persons and white persons: A 7-year nationwide study in patients with renal disease. Ann Intern Med. 1999;130:173–182
  10. Powe NR. To have and have not: Health and health care disparities in chronic kidney disease. Kidney Int. 2003;64:763–772
  11. Newsome BB, McClellan WM, Allison JJ. Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction. Am J Kidney Dis. 2008;52:251–261
  12. Newsome BB, McClellan WM, Coffey CS, Allison JJ, Kiefe CI, Warnock DG. Survival advantage of black patients with kidney disease after acute myocardial infarction. Clin J Am Soc Nephrol. 2006;1:993–999
  13. Daumit GL, Powe NR. Factors influencing access to cardiovascular procedures in patients with chronic kidney disease: Race, sex, and insurance. Semin Nephrol. 2001;21:367–376
  14. Gao SW, Oliver DK, Das N, et al. Assessment of racial disparities in chronic kidney disease stage 3 and 4 care in the Department of Defense health system. Clin J Am Soc Nephrol. 2008;3:442–449
  15. Xue JL, Eggers PW, Agodoa LY, Foley RN, Collins AJ. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged Medicare beneficiaries. J Am Soc Nephrol. 2007;18:1299–1306
  16. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315
  17. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14:2902–2907
  18. Mehrotra R, Kermah L, Fried L, Adler S, Norris K. Racial disparities in mortality outcomes in chronic kidney disease. J Am Soc Nephrol. 2008;April 2, [Epub ahead of print]
  19. Martins D, Wolf M, Pan D, et al. The prevalence of cardiovascular risk factors and the serum levels of vitamin D in the United States: Data from the NHANES III. Arch Intern Med. 2007;167:1159–1165
  20. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res. 2007;44:11–18
  21. Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008;April 9, [Epub ahead of print]
  22. Freedman BI. Susceptibility genes for hypertension and renal failure. J Am Soc Nephrol. 2003;14(suppl 2):S192–S194
  23. Suthanthiran M, Li B, Song JO. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A. 2000;97:3479–3484
  24. Schlitt L, Keitel HG. Pathogenesis of hyposthenuria in persons with sickle cell anemia or the sickle cell trait. Pediatrics. 1960;26:249–254
  25. Agarwal R. Ambulatory blood pressure and cardiovascular events in chronic kidney disease. Semin Nephrol. 2007;27:538–543
  26. McEwen BS, Seeman T. Protective and damaging effects of mediators of stress (Elaborating and testing the concepts of allostasis and allostatic load). Ann N Y Acad Sci. 1999;896:30–47
  27. McEwen BS. Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol. 2008;583:174–185
  28. Waterman AD, Browne T, Waterman BM, Gladstone EH, Hostetter T. Attitudes and behaviors of African Americans regarding early detection of kidney disease. Am J Kidney Dis. 2008;51:554–562
  29. Boulware LE. Challenges for public campaigns to improve the health of persons at high risk of developing CKD. Am J Kidney Dis. 2008;51:535–538

PII: S0272-6386(08)00996-7

doi: 10.1053/j.ajkd.2008.06.004

American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 205-208 , August 2008

Article Tools